From: Adverse events of inactivated COVID-19 vaccine in HIV-infected adults
Characteristic | Patients with HIV/AIDS (n = 259) | Dose 1(N = 259) | Dose 2 (N = 236) | ||||||
---|---|---|---|---|---|---|---|---|---|
With adverse events | Without adverse events | χ2 | P | With adverse events | Without adverse events | χ2 | P | ||
Age group | |||||||||
≤ 35 | 116 | 30 | 86 | 11 | 89 | ||||
> 35 | 143 | 29 | 114 | 1.14 | 0.29 | 13 | 123 | 0.13 | 0.72 |
Gender | |||||||||
Male | 240 | 55 | 185 | 21 | 197 | ||||
Female | 19 | 4 | 15 | 0.04 | 0.85 | 3 | 15 | 0.90 | 0.34 |
Marital status | |||||||||
Singe | 169 | 42 | 127 | 17 | 136 | ||||
Married | 36 | 6 | 30 | 3 | 31 | ||||
Other | 54 | 11 | 43 | 1.36 | 0.51 | 4 | 45 | 0.43 | 0.81 |
Occupation | |||||||||
Unemployment | 37 | 7 | 30 | 2 | 33 | ||||
Employment | 222 | 52 | 170 | 0.37 | 0.55 | 22 | 179 | 0.89 | 0.35 |
Education level | |||||||||
High school or lower | 76 | 17 | 59 | 6 | 62 | ||||
Higher than high school | 183 | 42 | 141 | 0.01 | 0.92 | 18 | 150 | 0.19 | 0.66 |
Comorbidities | |||||||||
Yes | 38 | 6 | 32 | 5 | 30 | ||||
No | 221 | 53 | 168 | 1.24 | 0.27 | 19 | 182 | 0.76 | 0.38 |
NNRTIs (NVP/EFV) | |||||||||
Yes | 216 | 47 | 169 | 17 | 180 | ||||
No | 43 | 12 | 31 | 0.77 | 0.38 | 7 | 32 | – | 0.09 |
INSTIs (EVG/DTG) | |||||||||
Yes | 26 | 5 | 21 | 1 | 22 | ||||
No | 233 | 54 | 179 | 0.21 | 0.65 | 23 | 190 | – | 0.48 |
PIs (LPV/r) | |||||||||
Yes | 14 | 5 | 9 | 5 | 8 | ||||
No | 245 | 54 | 191 | 0.74 | 0.39 | 19 | 204 | 9.00 | 0.003 |
CD4 | |||||||||
≤ 350 | 49 | 8 | 41 | 5 | 38 | ||||
> 350 | 210 | 51 | 159 | 1.43 | 0.23 | 19 | 174 | 0.12 | 0.73 |
HIV viral load | |||||||||
Undetectable | 208 | 49 | 159 | 19 | 172 | ||||
Detectable | 51 | 10 | 41 | 0.36 | 0.55 | 5 | 40 | – | 0.79 |